HER2 and EGFR indirectly activate PI3K, and amplification of HER2 is associated with the development of acquired resistance to EGFR-TKI occurring in 12% of active EGFR-mutated NSCLC patients who develop resistance [75]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.